Analyst Price Target is $2.25
▲ +435.71% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Advaxis in the last 3 months. The average price target is $2.25, with a high forecast of $2.25 and a low forecast of $2.25. The average price target represents a 435.71% upside from the last price of $0.42.
Current Consensus is
The current consensus among 1 investment analysts is to buy stock in Advaxis. This rating has held steady since May 2020, when it changed from a Hold consensus rating.
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.